Ocugen’s CFO Makes a Rare Open-Market Buy as Institutional Investors Pile In Ahead of Key Gene Therapy Data
29.06.2026 - 17:45:40 | boerse-global.de
When a chief financial officer buys her own company’s stock in the open market — the only insider transaction in six months — investors tend to take notice. At Ocugen, that June 15 purchase by Treerita Essalima Johnson-Greene comes just as the gene therapy developer is assembling a dense pipeline of clinical catalysts and a freshly fortified balance sheet. The CFO picked up 21,000 shares for roughly $25,800, lifting her stake by about 4% to 521,000 shares. No insider has sold a single share over the past half-year.
The market has already started to reward that conviction. Over the past seven trading days, Ocugen’s stock surged 25% to €1.42, though it remains about 40% below the 52-week high of €2.35 reached in March 2026. The rally has pushed the relative strength index to 70.7, nudging into overbought territory. That technical flag hasn’t deterred a wave of institutional buying: in the first quarter, 84 funds added to their positions while only 45 cut back. Millennium Management boosted its stake by more than 150%, adding over eight million shares. State Street increased by 143%, and RTW Investments bought roughly 6.7 million new shares.
The catalyst calendar explains why the smart money is piling in. Ocugen’s lead program, OCU400, is a mutation-agnostic gene therapy for retinitis pigmentosa, an inherited retinal disease that leads to blindness. Phase 1/2 data showed stable improvements in visual function over three years, and patient recruitment for the pivotal Phase 3 liMeliGhT study concluded in March 2026. The company plans to begin a rolling biologics license application (BLA) submission with the FDA in the third quarter of 2026, with topline data due in the first quarter of 2027. An approval could come as early as 2027, analysts say.
Should investors sell immediately? Or is it worth buying Ocugen?
Parallel to that, OCU410ST targets Stargardt disease, a rare macular degeneration that typically strikes in childhood. The Phase 2/3 program, known as GARDian3, has enrolled 63 patients and measures the reduction of atrophic lesions at 12 months. Interim data are expected in the third quarter of 2026, with topline results in the second quarter of 2027 and a BLA submission planned for mid-2027. A third program, OCU410, addresses geographic atrophy — an advanced form of dry age-related macular degeneration. Twelve-month Phase 2 data were released in January 2026, and Ocugen expects to launch a Phase 3 study later this year.
Canaccord analyst Whitney Ijem remains positive on the stock, even after trimming her price target slightly to $11. She sees three major ophthalmic indications backed by convincing clinical data and two ongoing registration studies as the foundation for long-term value. The consensus analyst price target stands at €10.02, implying upside of more than 600% from current levels — a figure that reflects the binary nature of biotech investing rather than a probability-weighted outcome.
That binary risk is tempered by a much-improved balance sheet. Ocugen closed a $130 million convertible note in April 2026, carrying a 6.75% coupon and maturing in 2034. Net proceeds came to roughly $112.6 million, of which about $32.7 million was used to fully repay an Avenue Capital loan. The rest extends the company’s operating runway into 2028, supporting the ambitious goal of submitting three BLAs in three years. Current cash and short-term investments stand at roughly $32 million — enough to keep programmes running while the convertible note provides the deeper financial cushion.
For now, the stock sits about 5% above its 50-day moving average. The next hard catalyst arrives in the third quarter of 2026, when Ocugen releases the OCU410ST interim analysis and begins the rolling BLA submission for OCU400. Until then, the shares trade on expectations — and on a rare insider buy that signals management’s own bet on the pipeline’s long shot. With annualised 30-day volatility of 57%, the ride will not be smooth, but the data on the horizon could shrink that 40% gap to the 52-week high in a hurry.
Ad
Ocugen Stock: New Analysis - 29 June
Fresh Ocugen information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
